To exploit the possibility of using MC3324 in BC with innate or acquired resistance to endocrine therapy, tamoxifen-insensitive-ERα positive BT474 cells were treated for 24 and 48 h with MC3324 alone or in combination with tamoxifen (Figure 3B–F). This evidence concerns the gene ESR1 and breast cancer.